Exten Industries (fka BB: EXTI)

[Patricia_1]

Dr. Parkinsons' words in news article 10/30/03

XenoTech Founder and CEO, Dr. Andrew Parkinson, states, "Our characterization studies corroborate and extend the earlier findings of MultiCell and Pfizer scientists presented at the 2002 ISSX meeting. Our results show that MCT's immortalized hepatocytes retain several functional drug metabolizing enzymes that previously had not been studied." Dr. Parkinson adds, "MCT's cell lines represent a breakthrough technology that has the potential to revolutionize how the pharmaceutical industry screens new drug entities, we anticipate significant worldwide interest in MCT's cell lines."